InMed Pharmaceuticals
INMInMed Pharmaceuticals is a clinical-stage biotechnology company focused on developing proprietary small molecule drug candidates that target the endocannabinoid system to treat diseases with high unmet medical needs.
Table of contents
Earnings
Next report
Sep 23, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
InMed Pharmaceuticals is a clinical-stage biotechnology company focused on developing proprietary small molecule drug candidates that target the endocannabinoid system to treat diseases with high unmet medical needs. The company utilizes a library of new chemical entities that act as preferential signaling ligands for CB1 and CB2 receptors, primarily addressing neurodegenerative, ocular, and dermatological conditions. Additionally, through its subsidiary BayMedica, the company operates a commercial B2B business producing and selling bulk rare, non-intoxicating cannabinoids for the health and wellness sector.
An early mover in the B2B rare cannabinoid supply market with a differentiated pharmaceutical pipeline targeting disease-modifying effects through receptor signaling.
Questions, answered.
- What is InMed Pharmaceuticals's market cap?
- InMed Pharmaceuticals (INM) has a market capitalization of $8.8M and trades on NASDAQ.
- Who are InMed Pharmaceuticals's competitors?
- InMed Pharmaceuticals's key competitors include Biogen, Eli Lilly, Annexon Biosciences, and others. These companies compete in similar markets and product categories.
- Who does InMed Pharmaceuticals partner with?
- InMed Pharmaceuticals's notable partners include Biogen, Eisai, Eli Lilly, and others.
- What subsidiaries does InMed Pharmaceuticals have?
- InMed Pharmaceuticals's subsidiaries include BayMedica, LLC.
- Where is InMed Pharmaceuticals headquartered?
- InMed Pharmaceuticals is headquartered in Canada and employs approximately 13 people. It has been publicly traded since 2020.